Financings of the Fortnight: Getting Comfortable In Genes
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor confidence in the potential for gene therapy is renewing, witness recent VC backing of GenSight and Audentes and bluebird bio’s IPO. Plus news on financings by Edimer, aTyr Pharma, Dicerna, and BioMotiv.
You may also be interested in...
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.